AHA/ASA 2026: acute ischaemic stroke
International AHA/ASA Current
2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke
Prabhakaran S, et al. Stroke. 2026;57:e316–e436
DOI 10.1161/STR.0000000000000513 · Summary checked against the source: 2026-11
At a glance
- Tenecteplase or alteplase within 4.5 h. Tenecteplase 0.25 mg/kg (max 25 mg) as a single bolus; alteplase 0.9 mg/kg (max 90 mg). Tenecteplase 0.4 mg/kg is not recommended. [1, A · e357]
- Treat a disabling deficit fast, whatever the NIHSS. Within 4.5 h, don't wait for CTA or perfusion imaging before IVT. [1, B-NR · e353]
- Mild non-disabling stroke (e.g. isolated sensory deficit): IVT gives no benefit. Use DAPT instead. [3: No benefit, B-R · e353]
- Extended-window IVT with imaging: wake-up stroke with DWI–FLAIR mismatch, or 4.5–9 h with salvageable penumbra on perfusion imaging. [2a, B-R · e359]
- EVT now covers large cores. ASPECTS 3–5 is Class 1 at 0–6 h, and at 6–24 h if age <80 without significant mass effect. ASPECTS 0–2 is 2a at 0–6 h. [e368–e369]
- Basilar artery occlusion, NIHSS ≥10: EVT within 24 h is Class 1. [1, A · e372]
- Don't push BP too low. After IVT, a target SBP <140 gives no benefit. After successful EVT, SBP <140 for 72 h is harmful. [e350]
- Glucose: aim for 140–180 mg/dL. Intensive control to 80–130 mg/dL gives no benefit and causes hypoglycaemia. [e352]
- Children get recommendations for the first time, including EVT from age 28 days. [e375–e376]
Emergency evaluation and imaging
Class 1 [e341–e346]
- NIHSS to measure the deficit at baseline and after reperfusion. [1, B-NR · e341]
- Emergent NCCT or MRI before any reperfusion treatment, to exclude haemorrhage and judge ischaemic burden (ASPECTS). Aim for imaging within 25 minutes. [1, A · e341]
- Suspected LVO: CTA/MRA from the neck to the head as fast as possible for EVT selection, up to 24 h from last known well. [1, A · e342]
- Don't wait for serum creatinine before contrast CTA or CTP. [1, B-NR · e341]
- Check blood glucose before IVT, since hypo- and hyperglycaemia mimic stroke. [1, B-NR · e353]
- ECG and troponin, but neither should delay IVT or EVT. [e346]
Class 2a [e341–e342]
- Wake-up or unknown-onset stroke >4.5 h: use MRI DWI–FLAIR mismatch to select for IVT. [2a, B-R · e341]
- 4.5–24 h: use CTP or MR DWI–PWI with automated software to select for IVT. [2a, B-R · e342]
- 6–24 h with LVO: adjunctive CTP or MRI can help select for EVT, if immediately available. [2a, A · e342]
- Children: MRI/MRA first. Use CT/CTA if MRI isn't available within 25 minutes. [2a, C-LD · e341]
General supportive care
| Area | Recommendation | Grade |
|---|---|---|
| Oxygen | Give if SpO₂ ≤94%, to keep it >94% | 1, C-LD |
| Routine oxygen without hypoxia (not for EVT): no benefit | 3: No benefit, B-R | |
| Head position | Flat (0°) versus 30° for 24 h: no benefit | 3: No benefit, B-R |
| Temperature | Treat hyperthermia to normothermia and look for its cause | 1, B-R |
| Induced hypothermia or prophylactic fever prevention: no benefit | 3: No benefit, B-R | |
| Glucose | Treat hypoglycaemia <60 mg/dL | 1, C-LD |
| Keep persistent hyperglycaemia at 140–180 mg/dL | 2a, C-LD | |
| IV insulin to reach 80–130 mg/dL: no benefit | 3: No benefit, A |
Adapted from AHA/ASA 2026 sections 4.1–4.5 [e347–e353]
Blood pressure
| Situation | Target | Grade |
|---|---|---|
| Before IVT | Lower to <185/110 mm Hg | 1, B-NR |
| Before EVT, no IVT | ≤185/110 mm Hg is reasonable | 2a, B-NR |
| After IVT, first 24 h | Keep <180/105 mm Hg | 1, B-R |
| After IVT | Intensive SBP <140: no benefit | 3: No benefit, B-R |
| During and 24 h after EVT | ≤180/105 mm Hg is reasonable | 2a, B-NR |
| After successful EVT (mTICI 2b–3) | SBP <140 for 72 h is harmful | 3: Harm, A |
| No reperfusion, BP <220/120 | Starting antihypertensives in the first 48–72 h: no benefit | 3: No benefit, A |
| No reperfusion, BP ≥220/120 | Benefit of treating in the first 48–72 h uncertain | 2b, C-EO |
| Comorbidity needing BP control (ACS, acute HF, dissection, post-IVT sICH, pre-eclampsia) | Treat early | 1, C-EO |
Adapted from AHA/ASA 2026 section 4.3 [e350]
Intravenous thrombolysis
Class 1: deciding on IVT [e353]
- Disabling deficit, whatever the NIHSS: treat, and faster treatment means better outcome. [1, A · e353]
- Within 4.5 h, start as quickly as possible, without waiting for multimodal imaging. [1, B-NR · e353]
- Early ischaemic change of mild to moderate extent (short of frank hypodensity) doesn't exclude IVT. [1, A · e353]
- Patients on single or dual antiplatelets can still have IVT. [1, B-NR · e353]
- Don't wait for an MRI to exclude microbleeds. [1, B-NR · e353]
- If disabling symptoms persist after correcting severe hypo- or hyperglycaemia, give IVT. [1, C-LD · e353]
- Be ready to treat bleeding and orolingual angioedema. [1, B-NR · e353]
Class 2a and 2b
- Don't delay IVT for coagulation results unless an abnormal result is suspected. [2a, B-NR · e353]
- 1–10 microbleeds on a previous MRI: IVT is reasonable. More than 10: usefulness uncertain. [2a/2b, B-NR · e353–e354]
- Sickle cell disease: IVT can be beneficial. [2a, B-NR · e362]
- LVO with penumbra at 4.5–24 h and EVT not possible: IVT may be beneficial. [2b, B-R · e359]
- Reteplase or mutant prourokinase instead of alteplase may be considered. [2b, B-R · e360]
- Children aged 28 days to 18 years, within 4.5 h with a disabling deficit: alteplase may be considered. [2b, C-LD · e354]
Class 3
- Mild non-disabling deficit within 4.5 h: no benefit from IVT. [3: No benefit, B-R · e353]
- Tenecteplase 0.4 mg/kg: no benefit. [3: No benefit, A · e357]
- Streptokinase: harmful, with higher early mortality. [3: Harm, A · e361]
- Sonothrombolysis, and adjunctive argatroban or eptifibatide with IVT: no benefit. [e361, e378, e384]
- IV aspirin within 90 minutes of starting IVT: harmful. [3: Harm, B-R · e378]
Doses and monitoring
| Agent | Dose |
|---|---|
| Alteplase | 0.9 mg/kg (max 90 mg) over 60 min, 10% as a bolus over 1 min |
| Tenecteplase | 0.25 mg/kg (max 25 mg) single IV push |
| Weight | Tenecteplase | Volume |
|---|---|---|
| <60 kg | 15 mg | 3 mL |
| 60 to <70 kg | 17.5 mg | 3.5 mL |
| 70 to <80 kg | 20 mg | 4 mL |
| 80 to <90 kg | 22.5 mg | 4.5 mL |
| ≥90 kg | 25 mg | 5 mL |
- Admit to an ICU or stroke unit.
- BP and neuro checks every 15 min for 2 h, every 30 min for 6 h, then hourly to 24 h.
- New headache, acute hypertension, vomiting or neurological worsening: stop the infusion and get an emergency CT.
- Delay NG tubes, urinary catheters and arterial lines if you safely can.
- CT or MRI at 24 h before starting antiplatelets or anticoagulants.
Adapted from AHA/ASA 2026 Table 7 [e358]
Extended window
- Unknown onset, within 4.5 h of symptom recognition: IVT if the DWI lesion is under one-third of the MCA territory with no marked FLAIR change.
- Not eligible for EVT, with salvageable penumbra on automated perfusion imaging: IVT if they woke up within 9 h of the midpoint of sleep, or are 4.5–9 h from last known well.
Contraindications and cautions
The 2026 guideline replaces the old fixed contraindication list with a graded table (Table 8): conditions where benefit usually outweighs bleeding risk, relative contraindications and absolute contraindications.
- CT with haemorrhage, or extensive clear hypodensity that explains the symptoms
- Moderate to severe traumatic brain injury within 14 days
- Intracranial or spinal surgery within 14 days
- Spinal cord injury within 3 months
- Intra-axial intracranial neoplasm
- Infective endocarditis
- Aortic arch dissection
- Severe coagulopathy: platelets <100 000/mm³, INR >1.7, aPTT >40 s or PT >15 s
- ARIA (amyloid-related imaging abnormalities) or amyloid immunotherapy
- Pre-existing disability or frailty
- DOAC within 48 h: safety unknown; may be considered after an individual risk assessment
- Ischaemic stroke within 3 months
- Previous ICH (higher risk with amyloid angiopathy)
- Major non-CNS trauma within 14 days, major surgery within 10 days, GI/GU bleeding within 21 days
- Intracranial arterial dissection, unruptured vascular malformation
- STEMI within 3 months, acute pericarditis, LA/LV thrombus
- Active systemic malignancy
- Pregnancy and post-partum: may be considered for moderate to severe stroke
- Dural puncture or non-compressible arterial puncture within 7 days
- TBI or neurosurgery 14 days to 3 months ago
- Extracranial cervical dissection
- Extra-axial neoplasm (e.g. meningioma), unruptured aneurysm
- Stroke during or just after angiography
- Remote GI/GU bleeding or MI
- Recreational drug use
- Uncertain diagnosis or possible mimic, if there's no absolute contraindication
- Moyamoya disease
Adapted from AHA/ASA 2026 Table 8 [e364–e367]
Endovascular thrombectomy
- Eligible for both IVT and EVT: give IVT, as fast as possible, and don't wait to see a response before EVT.
- Techniques: stent retriever, contact aspiration or both. Aim for eTICI 2b/2c/3 as early as possible. General anaesthesia or procedural sedation are both acceptable. [e373]
Who gets EVT
This mirrors AHA/ASA 2026 Figure 3. Adults have NIHSS ≥6 unless stated otherwise. "IDD" means insufficient data to determine.
| Time | ASPECTS | Pre-stroke mRS | EVT |
|---|---|---|---|
| 0–6 h | 6–10 | 0–1 | 1 |
| 2 | 2a | ||
| 3–4 | 2b | ||
| >4 | IDD | ||
| 0–6 h | 3–5 | 0–1 | 1 |
| ≥2 | IDD | ||
| 0–6 h | 0–2 | 0–1 | 2a (age <80, no significant mass effect) |
| ≥2 | IDD | ||
| 6–24 h | 6–10 | 0–1 | 1 |
| 6–24 h | 3–5 | 0–1 | 1 (age <80, no significant mass effect) |
| 6–24 h | any | ≥2 | IDD |
| >24 h | IDD |
| Occlusion | Time | Criteria | EVT |
|---|---|---|---|
| Dominant proximal M2 | 0–6 h | ASPECTS 6–10, mRS 0–1 | 2a |
| >6 h | IDD | ||
| Non-dominant M2, or distal vessel (M3, ACA, PCA) | 0–24 h | No EVT (3: No benefit) | |
| Basilar artery | 0–24 h | PC-ASPECTS ≥6, mRS 0–1, NIHSS ≥10 | 1 |
| 0–24 h | PC-ASPECTS ≥6, mRS 0–1, NIHSS 6–9 | 2b | |
| 0–24 h | mRS ≥2 | IDD |
| Age | Time | Criteria | EVT |
|---|---|---|---|
| ≤28 days | 0–24 h | LVO | IDD |
| 28 days to 5 years | 0–24 h | LVO, salvageable brain | 2b |
| 6–17 years | 0–6 h | LVO, salvageable brain | 2a |
| 6–17 years | 6–24 h | LVO, salvageable brain | 2a |
| 6–17 years | >24 h | IDD |
Adapted from AHA/ASA 2026 Figure 3 [e377]
Other EVT points
Antiplatelets and anticoagulants
Class 1
- Aspirin within 48 h of stroke onset. [1, A · e376]
- Non-cardioembolic stroke or TIA: antiplatelets rather than anticoagulation. [1, A · e378]
- Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), no IVT: aspirin + clopidogrel with a loading dose, started within 24 h, for 21 days, then single antiplatelet. [1, A · e378]
Class 3
- Aspirin instead of IVT or EVT in an eligible patient: harmful. [3: Harm, B-R · e378]
- Triple antiplatelet therapy (aspirin + clopidogrel + dipyridamole): harmful. [3: Harm, B-R · e378]
- Adding an antiplatelet to an oral anticoagulant in AF without recent stent or active CAD: harmful. [3: Harm, B-NR · e378]
- IV abciximab: harmful. Ticagrelor alone rather than aspirin: no benefit. [e378]
- Early anticoagulation within 48 h doesn't prevent early neurological worsening. [3: No benefit, A · e384]
DAPT for minor stroke and TIA
flowchart TD
A["Acute non-cardioembolic<br/>ischaemic stroke or TIA"] --> B{"Eligible for<br/>revascularisation?"}
B -->|Yes| T["Thrombolysis and<br/>thrombectomy sections"]
B -->|No| C{"Last known well<br/><24 h?"}
C -->|Yes| D{"NIHSS ≤3 or<br/>ABCD2 ≥4?"}
C -->|No| E{"Atherosclerosis<br/>(>50% stenosis)?"}
E -->|No| S1["SAPT"]
E -->|Yes| F{"24–72 h, and<br/>NIHSS ≤5 or ABCD2 ≥4?"}
F -->|Yes| P1["DAPT: clopidogrel + aspirin × 21 days<br/>Class 2a (INSPIRES)"]
F -->|No| S2["SAPT"]
D -->|No| G{"NIHSS 4–5?"}
G -->|No| S3["SAPT"]
G -->|Yes| P2["DAPT: clopidogrel + aspirin × 21 days<br/>Class 2a (INSPIRES, presumed atherosclerosis)<br/>OR ticagrelor + aspirin × 30 days<br/>Class 2b (THALES)"]
D -->|Yes| H["DAPT: clopidogrel + aspirin × 21–90 days<br/>Class 1 (CHANCE, POINT)<br/>OR ticagrelor + aspirin × 30 days<br/>Class 2b (THALES)"]
D -.->|"If allele testing done"| K{"CYP2C19 loss-of-<br/>function carrier?"}
K -->|No| H
K -->|Yes| P3["DAPT: ticagrelor + aspirin × 21 days<br/>Class 2b (CHANCE-2)"]
Adapted from AHA/ASA 2026 Figure 4 [e379]
Anticoagulation
In-hospital care
| Area | Recommendation | Grade |
|---|---|---|
| Stroke unit | Organised stroke unit with an interdisciplinary team | 1, B-R |
| Swallowing | Bedside swallow screen before any food or drink | 1, C-EO |
| Nutrition | Start enteral feeding within 7 days. NG tube first; PEG if unable to swallow safely for >2–3 weeks | 1, B-R / 2a, B-NR |
| DVT | Intermittent pneumatic compression in immobile patients | 1, B-R |
| Prophylactic UFH or LMWH is reasonable | 2a, B-R | |
| Elastic compression stockings: harmful | 3: Harm, B-R | |
| Depression | Screen with a structured inventory; treat with antidepressants and/or therapy | 1, B-NR / 1, B-R |
| Catheters | No routine indwelling bladder catheter | 3: Harm, C-LD |
| Antibiotics | No routine prophylactic antibiotics | 3: No benefit, A |
| Rehabilitation | Formal interdisciplinary rehabilitation | 1, A |
| Very early, high-dose mobilisation within 24 h: may be harmful | 3: Harm, B-R | |
| SSRIs to aid motor recovery: no benefit | 3: No benefit, A |
Adapted from AHA/ASA 2026 sections 5.1–5.7 [e389–e396]
Brain swelling and seizures
Class 1
- Large hemispheric or cerebellar infarct: discuss goals of care early, monitor closely in the first days, and transfer early to a centre with neurosurgery. [e397]
- Age ≤60, unilateral MCA infarct, worsening within 48 h despite medical treatment: decompressive craniectomy with dural expansion. [1, A · e398]
- Cerebellar infarct with obstructive hydrocephalus: ventriculostomy. [1, C-LD · e400]
- Cerebellar infarct with brainstem compression or volume ≥35 mL: suboccipital decompressive craniectomy. [1, B-NR · e400]
- Unprovoked seizure after stroke: start an antiseizure drug. [1, C-LD · e400]
Class 2a and 2b
Class 3
- Hypothermia, barbiturates or corticosteroids for brain swelling: harmful. [3: Harm, C-LD · e398]
- IV glibenclamide in large hemispheric infarction: no benefit. [3: No benefit, B-R · e398]
- Prophylactic antiseizure drugs: no benefit. [3: No benefit, C-LD · e400]
Clinical pearls
- Time windows: IVT ≤4.5 h (up to 9 h, or wake-up, with imaging). EVT ≤24 h for anterior LVO and basilar occlusion.
- Tenecteplase 0.25 mg/kg, max 25 mg, bolus. Alteplase 0.9 mg/kg, max 90 mg, 10% bolus then the rest over 60 min.
- BP <185/110 before IVT, <180/105 for 24 h after.
- Glucose before IVT. Keep 140–180 mg/dL; avoid hypoglycaemia (<60).
- Minor stroke or high-risk TIA: aspirin + clopidogrel within 24 h for 21 days.
- Malignant MCA infarct, age ≤60: craniectomy within 48 h of deterioration.
- No steroids for oedema, prophylactic antiseizure drugs, compression stockings or routine catheters.
Classes and levels of evidence
How AHA/ASA 2026 grades its recommendations. Adapted from AHA/ASA 2026 Table 2 [e324]. Hover over any class or level cited on this page to see what it means.
| Class | Strength | Meaning | Wording used |
|---|---|---|---|
| Class 1 | Strong | Benefit >>> risk | is recommended; is indicated, useful, effective or beneficial; should be performed or administered |
| Class 2a | Moderate | Benefit >> risk | is reasonable; can be useful, effective or beneficial |
| Class 2b | Weak | Benefit ≥ risk | may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain |
| Class 3: No benefit | Moderate | Benefit = risk (generally used only with level A or B) | is not recommended; is not indicated, useful or effective; should not be performed or administered |
| Class 3: Harm | Strong | Risk > benefit | potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered |
| Level | Meaning |
|---|---|
| Level A | High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies |
| Level B-R (randomised) | Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs |
| Level B-NR (non-randomised) | Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies |
| Level C-LD (limited data) | Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans |
| Level C-EO (expert opinion) | Consensus of expert opinion based on clinical experience |
Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.